Clinical characteristics and serum CA19 ‐9 combined with HE4 are valuable in diagnosing endometriosis‐associated ovarian cancer
International Journal of Gynecology & Obstetrics · 2023
DOI: 10.1002/ijgo.14695 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Gynecology & Obstetrics, 2023. Verfasst von Ting Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Endometriosis, Ovarian Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Innovative Team of Jiangsu Province, Jiangsu Province Policy Guidance Program (International Science and Technology Cooperation/Hong Kong, Macao and Taiwan Science and Technology Cooperation), National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
Endometriosis‐associated ovarian cancer (EAOC) is difficult to diagnose because of its low incidence, uncertain risk factors, and the absence of effective markers. This study aimed to investigate the clinical characteristics of EAOC and identify useful serological markers.
Methods
We retrospectively studied the clinical characteristics of patients with EAOC and ovarian endometriosis, obtained between January 1, 2011 and October 31, 2021. Univariate and multivariate logistic regression analyses were used to explore the relationship between clinical characteristics and EAOC. Receiver operating characteristic curves were applied to access the diagnostic value of serological markers in EAOC.
Results
In total, the clinical characteristics of 220 patients were obtained; 44 with EAOC and 176 with ovarian endometriosis. EAOC patients were older (46.20 vs. 36.26 years, P < 0.001) and had larger tumors (9.10 vs. 6.73 cm, P = 0.003) together with higher CA19‐9 (21.44 vs. 4.72 U/mL, P < 0.001) and HE4 levels (62.35 vs. 44.19 pmol/L, P < 0.001) when compared with ovarian endometriosis patients. Multivariate analysis showed that HE4 greater than 59.7 pmol/L, CA19‐9 greater than 8.5 U/mL, age 42 years or older, and tumor length 9.2 cm or longer were independent risk factors for EAOC. Significantly, CA19‐9 combined with HE4 had high sensitivity (72.73%) and specificity (78.41%) in diagnosing EAOC.
Conclusion
Age over 42 years, large ovarian tumor, serum CA19‐9 and HE4 are valuable in the diagnosis of EAOC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
ORCID-Profile: Lin Yuan
Förderung
- Innovative Team of Jiangsu Province
- Jiangsu Province Policy Guidance Program (International Science and Technology Cooperation/Hong Kong, Macao and Taiwan Science and Technology Cooperation)
- National Natural Science Foundation of China
- Natural Science Research Program of Higher Education Institutions in Jiangsu Province
- Scientific Research Project of Jiangsu Province Maternal and Child Health Association
- Traditional Chinese Medicine Science and Technology Development Project in Jiangsu Province
- Youth Scientist Fund of Jiangsu Basic Research Program
- 333 High-level Talents Training Project in Jiangsu Province
Zitieren
APA
Xu, T., Zhang, L., Jiang, Y., Wan, Y., Zhou, S., Sun, G., Cheng, W., & Yuan, L. (2023). Clinical characteristics and serum CA19 ‐9 combined with HE4 are valuable in diagnosing endometriosis‐associated ovarian cancer. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.14695
Vancouver
Xu T, Zhang L, Jiang Y, Wan Y, Zhou S, Sun G, et al. Clinical characteristics and serum CA19 ‐9 combined with HE4 are valuable in diagnosing endometriosis‐associated ovarian cancer. International Journal of Gynecology & Obstetrics. 2023. doi:10.1002/ijgo.14695
BibTeX
@article{Xu2023,
author = {Xu, Ting and Zhang, Lin and Jiang, Yi and Wan, Yicong and Zhou, Shulin and Sun, Guodong and Cheng, Wenjun and Yuan, Lin},
title = {Clinical characteristics and serum CA19 ‐9 combined with HE4 are valuable in diagnosing endometriosis‐associated ovarian cancer},
journal = {International Journal of Gynecology & Obstetrics},
year = {2023},
doi = {10.1002/ijgo.14695}
}
EUVIMED